As the first anti-obesity drug targeting multiple receptors, tirzepatide (Zepbound, Eli Lilly), a dual GIPR/GLP-1R agonist, was approved by the FDA in 2022
Medical Disclaimer: The information provided in this article is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment
It is not yet clear whether the proposed metabolic constraints are specific to GLP-1RA therapy or represent a broader feature of sustained caloric restriction and weight loss [49, 50]
Professor Dwyer has received lecture fees and advisory board payments from Astra-Zeneca, Bayer, Boehringer-Ingelheim and Eli-Lilly
But you can minimize these effects with a healthy, protein-packed diet